Literature DB >> 242911

Resistance to six aminoglycosidic aminocyclitol antibiotics among enterococci: prevalence, evolution, and relationship to synergism with penicillin.

S A Calderwood, C Wennersten, R C Moellering, L J Kunz, D J Krogstad.   

Abstract

Two hundred and three recent clinical isolates of enterococci were tested for susceptibility to streptomycin, kanamycin, amikacin, gentamicin, sisomicin, and tobramycin. Depending upon the source of the isolate, 36 to 54% of the enterococci demonstrated high-level resistance (minimal inhibitory concentration, >2,000 mug/ml) to streptomycin, 16 to 49% to kanamycin, and 0 to 14% to amikacin. None of the strains was highly resistant to gentamicin, sisomicin, or tobramycin. A comparison with isolates of enterococci obtained in 1968 revealed that there has been a decrease in prevalence of high-level resistance among organisms isolated from wound cultures in 1976. However, no decrease in resistance to streptomycin or kanamycin was demonstrated among blood or urine isolates. Penicillin, combined with gentamicin, sisomicin, or tobramycin, was synergistic against all 10 strains of Streptococcus faecalis subjected to formal testing. For streptomycin and kanamycin, the presence or absence of synergism with penicillin correlated with the absence or presence of high-level aminoglycoside resistance. High-level resistance to amikacin was seen in only 1 of the 10 strains. Nonetheless, combinations of penicillin plus amikacin failed to produce synergistic killing against 6 of the 10 strains. Indeed, the combination was synergistic only against those four strains that were susceptible to high levels of kanamycin.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 242911      PMCID: PMC429925          DOI: 10.1128/AAC.12.3.401

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Identification of streptococci: use of lysozyme and Streptomyces albus filtrate in the preparation of extracts for Lancefield grouping.

Authors:  B K Watson; R C Moellering; L J Kunz
Journal:  J Clin Microbiol       Date:  1975-03       Impact factor: 5.948

2.  Effects of ampicillin-amikacin and ampicillin-rifampin on enterococci.

Authors:  P B Iannini; J Ehret; T C Eickhoff
Journal:  Antimicrob Agents Chemother       Date:  1976-03       Impact factor: 5.191

3.  Antibiotic synergism against group D streptococci in the treatment of endocarditis.

Authors:  R W Ruhen; J H Darrell
Journal:  Med J Aust       Date:  1973-07-21       Impact factor: 7.738

4.  Studies on antibiotic synergism against enterococci. I. Bacteriologic studies.

Authors:  R C Moellering; C Wennersten; A N Weinberg
Journal:  J Lab Clin Med       Date:  1971-05

5.  Susceptibility of group D streptococcus (enterococcus) to 21 antibiotics in vitro, with special reference to species differences.

Authors:  P Toala; A McDonald; C Wilcox; M Finland
Journal:  Am J Med Sci       Date:  1969-12       Impact factor: 2.378

6.  Antibiotic synergism of enterococci. Relation to inhibitory concentrations.

Authors:  H D Standiford; J B De Maine; W M Kirby
Journal:  Arch Intern Med       Date:  1970-08

7.  Penicillin-streptomycin treatment of enterococcal endocarditis. A re-evaluation.

Authors:  E Jawetz; M Sonne
Journal:  N Engl J Med       Date:  1966-03-31       Impact factor: 91.245

8.  Recognition of group D streptococcal species of human origin by biochemical and physiological tests.

Authors:  R R Facklam
Journal:  Appl Microbiol       Date:  1972-06

9.  Penicillin-tobramycin synergism against enterococci: a comparison with penicillin and gentamicin.

Authors:  R C Moellering; C Wennersten; A J Weinstein
Journal:  Antimicrob Agents Chemother       Date:  1973-04       Impact factor: 5.191

  9 in total
  36 in total

1.  High-level, plasmid-borne resistance to gentamicin in Streptococcus faecalis subsp. zymogenes.

Authors:  T Horodniceanu; L Bougueleret; N El-Solh; G Bieth; F Delbos
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

Review 2.  Antimicrobial resistance among enterococci.

Authors:  D J Herman; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

3.  Comparison of the new MicroScan Pos MIC Type 6 panel and AMS-Vitek Gram Positive Susceptibility Card (GPS-TA) for detection of high-level aminoglycoside resistance in Enterococcus species.

Authors:  S Szeto; M Louie; D E Low; M Patel; A E Simor
Journal:  J Clin Microbiol       Date:  1991-06       Impact factor: 5.948

4.  Antimicrobial susceptibility changes in Enterococcus faecalis following various penicillin exposure regimens.

Authors:  T L Hodges; S Zighelboim-Daum; G M Eliopoulos; C Wennersten; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

5.  An analysis of group D streptococci recovered from cancer patients.

Authors:  V M Young; M J Morris; M R Moody; S C Schimpff; J W Gerster; P H Wiernik
Journal:  Infection       Date:  1978       Impact factor: 3.553

Review 6.  Pathogenicity of the enterococcus in surgical infections.

Authors:  P S Barie; N V Christou; E P Dellinger; W R Rout; H H Stone; J P Waymack
Journal:  Ann Surg       Date:  1990-08       Impact factor: 12.969

7.  Broad geographical distribution of homologous erythromycin, kanamycin, and streptomycin resistance determinants among group D streptococci of human and animal origin.

Authors:  D J LeBlanc; J M Inamine; L N Lee
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

Review 8.  Antibiotic combinations: should they be tested?

Authors:  G M Eliopoulos; C T Eliopoulos
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

9.  False susceptibility of enterococci to aminoglycosides with blood-enriched Mueller-Hinton agar for disk susceptibility testing.

Authors:  R D Jenkins; S L Stevens; J M Craythorn; T W Thomas; M E Guinan; J M Matsen
Journal:  J Clin Microbiol       Date:  1985-09       Impact factor: 5.948

Review 10.  Sisomicin, netilmicin and dibekacin. A review of their antibacterial activity and therapeutic use.

Authors:  P Noone
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.